



Metformin in Li Fraumeni Precision Prevention trial




(recruitment ongoing in UK genetics centres)

At-risk group:

224 adults (>16y) with confirmed diagnosis of LFS

Randomised 1:1



Intervention (112):

Daily metformin (up to 2g/day) for up to 5 years
Plus
Annual whole body MRI
surveillance

Clinical Endpoints:

Does metformin work?

Cancer-free and overall survival at 5 years. QOL

Control (112):

No metformin Annual whole body MRI surveillance





How does metformin work?

Effect on signalling pathways: HOMA-IR score, IGF1, PI3K cascade and OXPHOS genomic signature.


Tumorigenesis:

Circulating biomarkers of cancer including methylation and proteomic signatures, cfDNA



Why does mTP53 cause cancer?





Why metformin?

The NEW ENGLAND

BRIE

Increased Oxid in the Li–Frau

Ping-yuan Wang, Ph.D., Wenzhe Francesco S. Celi, M.D., Ross Are



Inhibiting mitochon cancer in a mouse syndrome



JNCI Cancer Spectrum (2020) 4(6): pkaa063

doi: 10.1093/jncics/pkaa063 First published online 18 July 2020 Article

Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome

Farzana L. Walcott, MD,^{1,7} Ping-Yuan Wang, PhD,² Christine M. Bryla, MSN,¹ Rebecca D. Huffstutler, CRNP,² Neha Singh, MD,³ Michael N. Pollak, MD,⁴ Payal P. Khincha, MD,⁵ Sharon A. Savage , MD,⁵ Phuong L. Mai , MD,^{5,8} Kevin W. Dodd, PhD,⁶ Paul M. Hwang , MD, PhD,² Antonio T. Fojo, MD, PhD,^{1,9,†} Christina M. Annunziata, MD, PhD^{1,†}

Ping-yuan Wang, ..., Antonio Tito Fojo, Paul M. Hwang



Hwang lab showed increased mitochondrial oxidative phosphorylation (OXPHOS) in LFS mice



- Seen in mice and LFS patients (*NEJM* 368(11):1027-32, 2013).
- Mouse model of LFS with mtDNA mutations (Polg^{mut}/p53^{172H/H}) LFS mice lived 2x longer. This effect was reproduced with metformin



Metformin inhibits oxidative phosphorylation in mitochondria via complex 1 of the electron transport chain. Also lowers circulating glucose, insulin and IGF1.


"I've reached out to [my daughter's] cancer predisposition team. One of her oncologists is not optimistic about metformin lowering the risk of cancer in LFS patients, [as it] will help obese patients in the trial lose weight, and that will lower the risk of cancer. So according to her, the results will be skewed."



$$H_3C$$
 NH_2
 NH
 NH
 NH_2
 NH_2
 NH_2



How does metformin work – directly or indirectly?





What translational questions is MILI asking?




- Does metformin prevent or delay the emergence of cancer in people with LFS provide evidence for licencing decision
- Why does cancer happen in LFS? insights into tumorigenesis from serial blood sampling, measurement of mitochondrial activity etc.
- Are some P53 mutations more cancer-forming than others? sequencing correlation with outcome to provide prognostic information
- What is the impact of yearly prevention and/or surveillance on quality of life? QOL data (fear of cancer scale)



Translational Data Platform








Update



- 40 patients recruited so far (need to recruit 224!) at 7 sites Oxford, Nottingham, Guys & St Thomas', Cambridge, Aberdeen, Southampton, Leicester. Sites in set up: Manchester, Royal Marsden, Edinburgh.
- Major problem with MRI surveillance scans
- NHSE -> internal consultation -> approved funding by Specialised Commissioning Services -> Wes Streeting funding freeze -> freeze lifted -> new internal consultation>
- July 2025 Funding approved for MILI MRI scans from NIHR's High Cost ETC panel
- Meanwhile revisiting end date and recruitment numbers: now require 156 participants (116 more) extended to July (?Dec) 2027



Channel 4 Documentary - October/November





MILI-Paed?

